The Serum CA-125 Concentration Data Assists in Evaluating CT Imaging Information When Used to Differentiate Borderline Ovarian Tumor from Malignant Epithelial Ovarian Tumors by Shin, Ji-Eun et al.
Korean J Radiol 12(4), Jul/Aug 2011 kjronline.org 456
The Serum CA-125 Concentration Data Assists in 
Evaluating CT Imaging Information When Used to 
Differentiate Borderline Ovarian Tumor from Malignant 
Epithelial Ovarian Tumors
Ji-Eun Shin, MD, Hyuck Jae Choi, MD, Mi-hyun Kim, MD, Kyoung-Sik Cho, MD
All authors: Department of Radiology and the Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 
138-736, Korea 
Objective: We wanted to evaluate the diagnostic value of serum CA-125 concentration, when used in combination with the 
preoperative contrast-enhanced CT results, to differentiate borderline ovarian tumors (BOTs) from stage I malignant 
epithelial ovarian tumors (MEOTs). 
Materials and Methods: Ninety-eight masses (46 BOTs and 52 stage I MEOTs) from 87 consecutive patients (49 with BOTs 
and 38 with stage I MEOTs) who had undergone preoperative contrast-enhanced computed tomography (CT) and surgical 
staging were evaluated retrospectively and independently by two radiologists. The preoperative serum CA-125 concentration 
was measured in all patients. The utility of analyzing serum CA-125 concentration in combination with the CT results was 
evaluated by receiver operating characteristic (ROC) curve analysis.
Results: An irregular tumor surface and lymphadenopathy were predictive of a MEOT. ROC analysis showed that the 
combination of CT data and the serum CA-125 level resulted in a higher diagnostic performance than did using the CT alone 
for differentiating BOTs from MEOTs. The areas under the curves (AUCs) without and with the use of the serum CA-125 level 
data were 0.67 (95% confidence interval [CI]: 0.57-0.77) and 0.78 (95% CI: 0.68-0.85), respectively, for reader 1 (p = 
0.029) and 0.71 (95% CI: 0.61-0.80) and 0.81 (95% CI: 0.72-0.89), respectively, for reader 2 (p = 0.009).
Conclusion: The serum CA-125 concentration is of additional diagnostic value when used in conjunction with the CT 
imaging results for differentiating BOTs from MEOTs.
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INTRODUCTION
Borderline ovarian tumors (BOTs) are semi-malignant 
ovarian tumors with a more indolent clinical course than 
is shown by malignant epithelial ovarian tumors (MEOTs) 
(1). Unlike MEOTs, BOTs commonly affect women in their 
fourth decade and they tend to be localized in the ovary 
at the initial presentation, and this results in an excellent 
prognosis (2, 3). The principal treatment for BOTs is surgical 
resection of the primary tumors without adjuvant therapy 
(4), and the younger patients who desire to maintain 
ovarian function often receive unilateral oophorectomy 
(4). In contrast, the primary surgical treatment for MEOTs 
is total abdominal hysterectomy, bilateral salpingo-
oophorectomy and thorough surgical staging (5), followed Korean J Radiol 12(4), Jul/Aug 2011 kjronline.org 457
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by adjuvant chemotherapy (6). Thus, the accurate 
preoperative differentiation of BOTs from MEOTs is important 
for determining the treatment methods for individual 
patients. 
CT has been extensively used for making the preoperative 
diagnosis of ovarian cancer patients. Although several 
reports have evaluated the ability of CT to differentiate 
BOTs from MEOTs (7-11), those studies found that imaging 
alone could not easily distinguish between these two types 
of tumor. In one randomized, multicenter prospective 
study involving 1,066 patients, the serum concentration 
of CA-125 was lower in the patients with BOTs than that 
in the patients with MEOTs (12). Although these findings 
suggested that addition of CA-125 measurements to the 
CT results could improve the differentiation of BOTs from 
MEOTs, to the best of our knowledge, there have been 
no studies that have assessed the additional diagnostic 
value of the CA-125 level. We investigated the utility of 
this parameter, used in conjunction with CT imaging, for 
differentiating BOTs from MEOTs.
MATERIALS AND METHODS
Study Population
This retrospective analysis involved 98 masses (46 BOTs 
and 52 stage I MEOTs) in 87 consecutive patients with 
histologically confirmed BOTs (n = 43; mean age, 52 years; 
range, 14 to 79 years) and surgically confirmed FIGO stage 
I MEOTs (n = 44; mean age, 52 years; range, 27 to 73 
years) and all patients were recruited between January 
2001 and March 2008. None of these patients had any 
contraindications to surgery and all of them had Eastern 
Cooperative Oncology Group performance scores of 0-1. 
CT Technique
All patients underwent CT using a single-channel detector 
helical CT scanner (Somatom Plus-S, Siemens, Germany) 
from the diaphragm to the symphysis pubis, with a beam 
collimation of 5 mm or 7 mm, a pitch of 1.5 or 1.7, and an 
image reconstruction increment of 5 mm. Approximately 
600-900 ml of contrast material (2% barium sulfate 
suspension, E-Z-CAT; E-Z-Em, Westbury, NY) was orally 
administered to each patient 30-40 min before scanning. 
Starting approximately 120 sec before scanning, all patients 
were intravenously given 100-120 ml of a second contrast 
medium (iopromide, Ultravist 300, Schering, Berlin, 
Germany) at a rate of 3.0 ml/sec. 
Analysis and Statistics
The CT images were retrospectively and independently 
interpreted by two radiologists  with nine years and one 
year of clinical experience, respectively, in gynecologic 
imaging, including CT imaging. Both readers were informed 
of the patients’ medical history in that they were aware 
that all patients had undergone surgery for ovarian tumors 
(BOTs or MEOTs), but both were blinded to the pathologic 
results and the serum CA-125 concentrations. The serum CA-
125 level was measured after the CT scan within two weeks 
(range, 3-31 days). The serum CA-125 level was analyzed 
in a gamma counter (Cobra II; Packard, Meriden, CT). The 
assessed imaging features included the presence of ascites, 
pleural effusion, peritoneal implantation, enlarged lymph 
nodes (short axis diameter ≥ 1 cm), the character of the 
mass (cystic, mainly [> 2 of 3] cystic or mainly [> 2 of 3] 
solid, and a smooth or irregular appearance of the surface) 
and the mass size (13-17). 
The CT images were visually interpreted using a 
5-point grading system: 0 = BOT, 1 = probably BOT, 2 = 
indeterminate, 3 = probably malignant, 4 = malignant. Each 
reader initially evaluated the CT images alone, followed 3 
month later by a combined evaluation of the CT images and 
the CA-125 concentrations.
The degree of agreement between the two readers 
was measured using k statistics. The parameters of the 
combined CT and serum CA-125 level for differentiating 
BOTs from stage I MEOTs were obtained with the probability 
from the bivariate multiple logistic regression analysis. The 
probability estimation is primarily aimed at establishing 
conditions under which the true correlation structure may 
remain unknown; in such an analysis, standardized and 
non-standardized coefficients are obtained using logistic 
regression analysis. The utility of adding the serum CA-
125 concentration data to the CT findings was evaluated 
by means of receiver operating characteristic (ROC) curve 
analysis and measurement of the interobserver agreement. 
The analysis was performed using STATA (version 9.2; Stata 
Corp, TX). A p value < 0.05 was considered statistically 
significant.
RESULTS
Detailed histologic analyses of the 98 ovarian masses 
showed that 37 were serous adenocarcinomas, nine were 
mucinous adenocarcinomas, 21 were serous BOTs and 31 
were mucinous BOTs. The mean serum CA-125 concentration Korean J Radiol 12(4), Jul/Aug 2011 kjronline.org 458
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was significantly higher in the patients with MEOTs (421.0 
± 704.8 U/ml, range, 6.3 to 3670 U/ml) than that in the 
patients with BOTs (54.7 ± 64.5 U/ml, range, 4.4 to 343 U/
ml) (p = 0.0003) (Fig. 1).
In differentiating MEOTs from BOTs, the AUCs with and 
without the use of the serum CA-125 concentrations were 
0.67 (95% confidence interval [CI]: 0.57-0.77) and 0.78 
(95% CI: 0.68-0.85), respectively, for reader 1 (p = 0.029) 
(Fig. 2A) and 0.71 (95% CI: 0.61-0.80) and 0.81 (95% CI: 
0.72-0.89), respectively, for reader 2 (p = 0.009) (Fig. 2B). 
The weighted k statistics for the interobserver agreement 
were 0.74 for the analysis of the CT images only and 0.91 
for the analysis of both the CT images and the serum CA-
125 concentration. The sensitivity, specificity and positive 
and negative predictive values for differentiating BOTs 
from MEOTs, using the cutoff points of the ROC curves, are 
shown in Table 1. The sensitivities for readers 1 and 2 were 
91% and 48%, respectively, for CT images only, and 65% 
and 83%, respectively, for CT imaging plus CA125 data. 
The specificities for readers 1 and 2 were 31% and 87%, 
respectively, for using the CT images only, and 79% and 
71%, respectively, for using the CT imaging plus the CA-
125 information. Although the inclusion of the CA-125 
concentration decreased the sensitivity of reader 1, the rise 
in specificity for this reader indicated that more MEOTs were 
correctly diagnosed and that the overall AUC had increased. 
In addition, the huge discrepancies in specificity for readers 
1 (31%) and 2 (87%) decreased after the serum CA-125 
concentration was included in analysis (79% for reader 1 
and 71% for reader 2). 
From the ROC curve, we found that the cut-off CA-125 
concentration for differentiating MEOTs from BOTs was 152 
U/ml, although considerable overlap in the CA-125 level 
was evident between the patients with the two conditions.
The evaluated imaging findings for MEOTs and BOTs are 
summarized in Table 2. The presence of surface irregularity 
(p = 0.0039 for reader 1 and p = 0.0012 for reader 2) and 
lymph node enlargement (p = 0.0039 for both readers) were 
imaging features that significantly differed between the 
MEOTs and BOTs for both readers (Figs. 3, 4). However, as 
the frequencies of such findings were relatively low, and 
significant between-conditions overlap was evident, the 
clinical significance is likely to be minimal.
The diagnostic importance of peritoneal implants differed 
between the two readers. In contrast, general agreement 
was achieved for the other imaging findings (e.g., ascites, 
pleural effusion and the character of the mass). Both 
readers found that the diameters of the BOTs were larger 
than those of the stage I MEOTs (Table 2). 
In addition, no tumor involvement of the lymph nodes 
and peritoneal implants in all patients were confirmed on 
the pathologic reports.
DISCUSSION
CT has been extensively utilized for making the 
preoperative diagnosis of ovarian tumors. However, CT was 
found to be of lower diagnostic accuracy for differentiating 
BOTs from MEOTs (7-11). Moreover, to the best of our 
knowledge, no previous studies have assessed whether the 
addition of the serum CA-125 concentration data to the CT 
findings increases the accuracy of differentiating BOTs from 
Fig. 1. Box plots showing CA-125 serum concentrations in 
patients with stage I malignant epithelial ovarian tumors 
(MEOTs) and borderline ovarian tumors (BOTs). Mean serum CA-
125 levels in patients with malignant epithelial ovarian tumors 
and borderline ovarian tumors were 421.0 U/ml and 54.7 U/ml, 
respectively (p = 0.0003).
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MEOTs, relative to the use of the CT information alone. 
Elevated serum concentrations of glycoprotein CA-125, 
up to ≥ 30 U/ml, are considered to indicate the presence 
of a malignant ovarian tumor (18, 19). However, the 
serum CA-125 level alone cannot differentiate between 
benign and malignant tumors. For example, high serum CA-
125 concentrations have been observed in some patients 
with benign ovarian masses, as well as in patients with 
endometriosis, tubo-ovarian abscesses and fibromas, and all 
of which irritate the peritoneal surface (12). In addition, 
some patients with ovarian tumors, including BOTs, can 
have low serum CA-125 concentrations. For these reasons, 
the serum CA-125 level alone can be of low diagnostic 
accuracy when used to differentiate between benign and 
malignant ovarian masses. However, in patients with 
primary, invasive, ovarian tumors and who have higher 
serum CA-125 concentrations than do those patients with 
borderline ovarian tumors, the CA-125 level may be useful 
for differentiating between BOTs and MEOTs (12). 
We found that the addition of the serum CA-125 
concentration data to the CT imaging information increased 
the accuracy of differentiating BOTs from MEOTs. The mean 
serum CA-125 concentrations in the patients with BOTs 
and MEOTs were 54.7 U/ml and 421 U/ml, respectively (p = 
0.0003). We also found that the inter-observer agreement 
was higher when the serum CA-125 data were added to the 
CT image results (k = 0.91) than when the CT images alone 
were evaluated (k = 0.74). 
The sensitivities afforded by CT imaging alone, as 
assessed by the two readers, were 91% and 48%, and the 
specificities were 31% and 87%, respectively. Although 
inclusion of the CA-125 concentration data decreased the 
sensitivity for reader 1, the specificity rose, indicating that 
more MEOTs were correctly diagnosed and that the overall 
AUC had increased. In addition, the huge discrepancy in the 
specificity between the two readers fell when the serum CA-
125 data was included.
Our findings indicate that evaluation of patients using a 
combination of the CT data and the CA-125 concentration 
results in more reproducible and accurate differentiation 
of BOTs from MEOTs. Thus, the serum CA-125 concentration 
should be used to assist the differentiation of patients with 
Fig. 2. Receiver operating characteristic curve analyses showing additional utility of CA-125 concentration data for differentiating 
between borderline ovarian tumors and stage I malignant epithelial ovarian tumors. Dotted lines = diagnoses performed using both 
CT images and serum CA-125 concentrations. Solid lines = diagnoses made by CT imaging alone. 
A. Areas under curve for reader 1 were 0.71 and 0.81 before and after addition of serum CA-125 concentration data, respectively, to 
diagnoses obtained using CT imaging (p = 0.009). B. Areas under curve for reader 2 were 0.67 and 0.78 before and after addition of 
serum CA-125 concentration data, respectively, to diagnoses obtained using CT imaging (p = 0.029). *Reader 1_ pre = diagnoses using CT 
images only, reader 1 _ post = diagnoses using CT images and CA-125 concentration data, reader 2_ pre = diagnoses by CT images only, 
reader 2 _ post = diagnoses by CT images and CA-125 concentrations
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Table 1. Accuracy of CT Imaging, and Combined CT Data 
and Serum CA-125 Concentration, for Differentiating 
Stage I Malignant Epithelial Ovarian Tumors from 
Borderline Ovarian Tumors
Condition Sensitivity (95% CI) Specificity (95% CI)
Reader 1
CT* 91 (79-98) 31 (19-45)
CT & CA-125** 65 (50-79) 79 (65-89)
Reader 2
CT* 48 (33-63) 87 (74-94)
CT & CA-125**  83 (69-92) 71 (57-83)
Note.— *CT imaging only, **CT imaging combined with serum 
CA-125 level. CI = confidence intervalKorean J Radiol 12(4), Jul/Aug 2011 kjronline.org 460
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ovarian masses.
We also found that the presence of surface irregularities 
and lymph node enlargement were specific features 
indicative of MEOTs. However, the percentages of masses 
with surface irregularities (15% for reader 1 and 24% for 
reader 2) and enlarged lymph nodes (7% for both readers) 
were relatively low, with significant overlaps between the 
MEOTs and BOTs; thus, these features are unlikely to be of 
useful clinical significance. Both readers found that the 
BOTs were significantly larger than the MEOTs, but the size 
range substantially overlapped, and we were unable to 
determine a cutoff value. Reader 1 found that peritoneal 
implants were more frequent for the MEOTs than for the 
BOTs (p = 0.0007), but reader 2 disagreed (p = 0.3388). 
Moreover, peritoneal implants were rarely found on the CT 
images (20% for reader 1 and 15% for reader 2). Together, 
these findings indicate that the peritoneal implant status 
could not be used to differentiate between BOTs and MEOTs
Our study had several limitations. First, our study had 
a retrospective design and all included patient underwent 
Table 2. Imaging Features of Stage I Malignant Epithelial Ovarian Tumors and Borderline Ovarian Tumors
Reader 1
P
Reader 2
P
BOT MEOT BOT MEOT 
Ascites   5 (10)   5 (11) 1.0000 10 (19)   7 (15) 0.7900
Pleural effusion 0 (0) 0 (0) 1.0000 1 (2) 0 (0) 1.0000
Peritoneal implant 0 (0)   9 (20) 0.0007 4 (8)   7 (15) 0.3388
Enlarged lymph node 0 (0)   7 (15) 0.0039 0 (0)   7 (15) 0.0039
Mass character 0.4945 0.1583
Cystic 29 (56)   7 (15)   8 (15) 2 (4)
Mainly cystic 21 (38) 26 (57) 40 (77) 29 (63)
Mainly solid 2 (4) 11 (24) 3 (6) 11 (24)
Solid 0 (0) 2 (4) 0 (0) 4 (9)
Surface appearance 0.0039 0.0012
Smooth   52 (100) 39 (85) 51 (98) 35 (76)
Irregular 0 (0)   7 (15) 1 (2) 11 (24)
Diameter 12.6 cm (2-31)* 8.9 cm (8-20) 0.0017  13.2 cm (2-30) 9.2 cm (0.5-24) 0.0012
Total 52 46 52 46
Note.— Numbers in parentheses are percentages. *Mean (range). BOT = borderline ovarian tumor, MEOT = FIGO stage I malignant 
epithelial ovarian tumor
A B
Fig. 3. Images from 47-year-old woman with mucinous borderline ovarian cancer. 
A. Axial postcontrast CT scan of mid-pelvic level showing well-defined mass (arrows) with solid portion (arrowheads), and this was later 
found to be mucinous fluid by histopathologic examination. All of ascites, peritoneal implantation and pleural effusion were absent on 
CT images. Serum CA-125 concentration was 7 U/ml. B. Photograph of cut surface of ovarian mass showing mucinous fluid within mass.Korean J Radiol 12(4), Jul/Aug 2011 kjronline.org 461
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preoperative CT scanning. Considering that CT scans are 
usually done for the characterization or further evaluation 
of ovarian masses, there could be selection bias in our 
study population. Second, we did not use objective grading 
standards for the CT results or the CA-125 levels. Third, 
we currently do not have an objective method to solve 
the substantial overlap between the serum CA-125 level 
and CT imaging findings, as is observed clinically, and this 
indicates the need for further investigation.
In conclusion, the addition of the serum CA-125 
concentration data to the CT imaging results was of 
significant diagnostic value for differentiating BOTs from 
MEOTs.
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